220 likes | 341 Views
Adjuvant radiochemotherapy in head and neck tumors H. Christiansen and C. F. Hess. Department of Radiotherapy Goettingen University. Adjuvant RT pN+. Local control Cause-specific survival. Surgery + RT. Surgery + RT. Surgery. Surgery. Lundahl et al. Int J Radiat Oncol Biol Phys 1998.
E N D
Adjuvant radiochemotherapy in head and neck tumorsH. Christiansen and C. F. Hess Department of RadiotherapyGoettingen University
Adjuvant RT pN+ Local control Cause-specific survival Surgery + RT Surgery + RT Surgery Surgery Lundahl et al. Int J Radiat Oncol Biol Phys 1998
Risk factors for locoregional recurrence after radical surgery • Tumor size (>T2) • Lymph node involvement (N+) • Positive margins after surgery
Radio-chemotherapy Radio-chemotherapy Radiotherapy Radiotherapy Progression-free survival Overall survival Bernier et al. N Engl J Med 2004
EPO for correction of anaemia(locoregional progression free survival) 12 24 36 48 60 Henke et. al. Lancet 2003
Toxicity* *Bernier et al. N Engl J Med 2004
Application forms of concomitant cisplatin chemotherapy • 100 mg/m² on days 1, 22, 43(Cooper et al. 2004) • weekly 50 mg/m²(Bachaud et al. 1996) → more intensive chemotherapy leads to increased toxicity
Prophylaxis of side effects Amifostine Patient Benefit Questionnaire (PBQ) locoregional control Brizel et. al. JCO 2000
G-CSF Local control Months Staar et al. Int J Radiat Oncol Biol Phys 2001 • Patients receiving G-CSF showed reduced mucosal toxicities (p=0.066)
Nutrition support BNS = baseline nutrition support before treatment initiationTNS = nutrition support during treatment onlyno NS = no nutrition support Rabinovitch et. al. Head Neck 2006 (in press)
Pilocarpin • Pilocarpine can maintain and protect unstimulated salivary flow • however, there was no positive impact on the QOL outcome for patients taking pilocarpine Fisher et. al. Int J Radiat Oncol Biol Phys 2003
Modern 3–D radiotherapy technique CTV = primary tumour region and cervical and supraclavicular lymph nodes Gregoire et. al. 2004
Adjuvant RT after laser surgery – the University of Goettingen experience(n=208; 40 stage III, 168 stage IV) Pradier, Christiansen et. al. Int J Radiat Oncol Biol Phys 2005
Hb ≥ 13.5 g/dl Survival Hb < 13.5 g/dl Preradiotherapeutic hemoglobin level – significant influence on prognosis (Stage III/IV) Pradier, Christiansen et. al. Int J Radiat Oncol Biol Phys 2005
median Hb-level 14.7 g/dl Hb ≥ 14.7 g/dl Survival Hb < 14.7 g/dl Christiansen, Pradier Unpublished data 2006 Preoperative hemoglobin level – no significant influence on prognosis (Stage III/IV)
RT vs. RCT in the adjuvant situation after laser surgery (n=48) the University of Goettingen experience Christiansen, Pradier Unpublished data 2006
Summary Addition of chemo- to adjuvant radiotherapy • Increased local control (increased survival?) • Main agent: Cisplatinum (different modes of application) • Modestly increased toxicity (prophylaxis by Amifostine?) • Considerable impact of RT technique
Future aspects • New agents e.g. EGFR blocking antibody (Cetuximab) • Patient selection via predictive factors • High precision RT-techniques • Potential impact of laser surgery on treatment efficacy (via better local perfusion) and better QOL